Prime-boost strategy for vaccine development against both Plasmodium vivax and P. falciparum using MSP-1 19 (Figure 1 ). In addition, both antigens significantly increased IFNγ responses in mice immunized with both antigens in combination using prime-boost strategy (Figure 2 ). rPfMSP-1 19 when combined with rPvMSP-1 19 was not affects antibodies or IFNγ and IL-10 responses in prime-boost strategy.
Conclusion
The present results are encouraging to develop a multispecies human malaria vaccine against asexual blood stage of P. vivax and P. falciparum. Further study is needed to evaluate the protective efficacy of this vaccine in non-human primates. Mehrizi et al. Malaria Journal 2010, 9(Suppl 2):P64 http://www.malariajournal.com/content/9/S2/-P64
